Time to hematologic recovery predicts survival in chronic lymphocytic leukemia patients treated with fludarabin, cyclophosphamide and rituximab – 11 years of real‐world experience
Hematological Oncology(2021)
Abstract
Introduction: Chemotherapy-free regimens are frequently the first choice in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment. Despite some concerns about short and long-term toxicity, chemotherapy is still a highly valuable option in a specific subset of patients. We wanted to assess efficacy, overall and progression free survival (OS and PFS), short and long-term toxicity and predictors of response in the real-life setting. Methods: Unicentric, retrospective study of CLL/SLL patients treated with fludarabin, cyclophosphamide, rituximab (FCR) from July 2008 until April 2019. Results: Sixty-nine patients were included, 74% were male, median age of 58 year (IQR 50-63). Seventy-eight percent were treated in first line setting, 22% had relapsed/refractory (R/R) disease. Before treatment, FISH analysis was performed in 67 patients: 4.5% had (del)17p, 14.9% had del(11q), 37.3% had (del)13q, 28.4% had triss12 and 29.9% had normal cytogenetic analysis. We found 2/45 patients with TP53 mutation and 19/39 patients had mutated IgHV. Complete response (CR) was reached in 41.8%, CR with incomplete marrow recovery in 34.3%, partial response in 13.4%, stable and progressive disease in 3% and 7.5%, respectively. Minimal residual disease (MRD) was negative in 19/33 patients. Median follow-up of 59.6 months, 1st line median PFS of 55.3 months and median OS not reached, with 80.2% of patients alive at median follow up time. On the R/R setting, median PFS and OS were 41.5 and 58.3 months respectively. Negative MRD had a positive impact on survival (median PFS not reached vs. 31.3 M, p = 0.015), as well as cytogenetic analysis (p = 0.003). Half of the patients received 6 cycles and more than 75% received at least 4 cycles. Dose reduction was needed in 18% of the patients, and 36% had some delay in treatment schedule. Hematologic toxicity grade ≥3 was found in 62%: anaemia 4.3%, neutropenia 49%, thrombocytopenia 24.6%. Nearly half had complete hematologic recovery (49.7%) with median time to recovery of 124 days. Of note, PFS was longer in patients who took more than 124 days for hematologic recovery (median PFS 110.9 vs 42.7 months, p < 0.001; Fig 1). Time to hematologic recovery (HR) predicts progression free survival Infeccious adverse events grade ≥3 were found in 7.5% of patients, and 17.4% of opportunistic infections (epstein-barr, herpes zoster, P.jiroveci). Second neoplasms were found in 13% of patients: 2 acute leukemias, 3 adenocarcinomas and 4 skin neoplasms. There were 20 fatalities: 9 for progressive disease (median time to death 49 months), 3 for infectious adverse events (17-20 days after treatment), 3 for 2nd neoplasms and 5 patients for non-related causes. Conclusions: In the real-world setting with a long follow up time, FRC attained 76% of CR in 1st line therapy, with long lasting remissions and an acceptable toxicity profile. Cytogenetic analysis, negative MRD and, interestingly, longer time to hematologic recovery had a positive impact in PFS. EA – previously submitted to regional or national meetings (up to 1000 attendees). Keywords: Diagnostic and Prognostic Biomarkers, Late Effects in Lymphoma Survivors, Chronic Lymphocytic Leukemia (CLL) No conflicts of interests pertinent to the abstract.
MoreTranslated text
Key words
lymphocytic leukemia patients,hematologic recovery predicts survival,fludarabin,cyclophosphamide
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined